Anaplastic Large Cell Lymphoma (Alcl) Therapeutics Market with Worldwide Industry Analysis to 2026
- Submitted by: ankush321
- Views: 83
- Category: Science
- Date Submitted: 07/29/2016 03:31 AM
- Pages: 3
- Report this Essay
Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably. Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called a tumor. The two type of lymphocytes that can develop into lymphoma – B-lymphocytes (B-cells) and T-lymphocytes (T-cells). Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma and a common subtype of T-cell lymphoma. ALCL consists of only 2% of NHLs and approx. 20% of T-cell lymphomas. ALCL symptoms includes fever, painless swelling of lymph nodes, weight loss, tiredness, backache and excessive night sweats. It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL
According to National Cancer Institute, in the 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. NHL is the sixth most commonly diagnosed cancer in both men and women in the US. In 2015, it is estimated that there will be 71,850 new cases of NHL (39,850 men and 32,000 women) and 19,790 deaths from NHL. According to GLOBOCAN 2012 estimates the incidence and mortality rate of NHL is 2.7% and 2.4% respectively.
Following drugs are being tested for ALCL:
• Alisertib (MLN8237)
• Bortezomib (Velcade)
• Combination of brentuximab vedotin and chemotherapy
• Crizotinib (Xalkori)
The global ALCL therapeutics market is segmented on the basis of route of administration, therapeutic areas and region
Segmentation based on Disease Type
• Primary ALCL
• Relapsed ALCL
Request Free Report @ http://www.futuremarketinsights.com/reports/sample/rep-gb-1655
Segmentation based on...
According to National Cancer Institute, in the 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. NHL is the sixth most commonly diagnosed cancer in both men and women in the US. In 2015, it is estimated that there will be 71,850 new cases of NHL (39,850 men and 32,000 women) and 19,790 deaths from NHL. According to GLOBOCAN 2012 estimates the incidence and mortality rate of NHL is 2.7% and 2.4% respectively.
Following drugs are being tested for ALCL:
• Alisertib (MLN8237)
• Bortezomib (Velcade)
• Combination of brentuximab vedotin and chemotherapy
• Crizotinib (Xalkori)
The global ALCL therapeutics market is segmented on the basis of route of administration, therapeutic areas and region
Segmentation based on Disease Type
• Primary ALCL
• Relapsed ALCL
Request Free Report @ http://www.futuremarketinsights.com/reports/sample/rep-gb-1655
Segmentation based on...